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Background: Although several countries, including Germany, have established newborn hearing screening
programmes for early detection and treatment of newborns with hearing impairments, nationwide tracking systems
for follow-up of newborns with positive test results until diagnosis of hearing impairment have often not been
implemented. However, a recent study on universal newborn hearing screening in Bavaria showed that, in a high
proportion of newborns, early diagnosis was only possible with the use of a tracking system. The aim of this study
was, therefore, to assess the cost-effectiveness of tracking newborns with bilateral hearing impairment in Bavaria.
Methods: Data from a Bavarian pilot project on newborn hearing screening and Bavarian newborn hearing
screening facilities were used to assess the cost-effectiveness of the inclusion of a tracking system within a
newborn hearing screening programme. A model-based cost-effectiveness analysis was conducted. The time
horizon of the model was limited to the newborn hearing screening programme. Costs of the initial hearing
screening test and subsequent tests were included, as well as costs of diagnosis and costs of tracking. The outcome
measure of the economic analysis was the cost per case of bilateral hearing impairment detected. In order to
reflect uncertainty, deterministic and probabilistic sensitivity analyses were performed.
Results: The incremental cost-effectiveness ratio of tracking vs. no tracking was €1,697 per additional case of
bilateral hearing impairment detected.
Conclusions: Compared with no tracking, tracking resulted in more cases of bilateral hearing impairment detected
as well as higher costs. If society is willing to pay at least €1,697 per additional case of bilateral hearing impairment
detected, tracking can be recommended.
Keywords: ‘Neonatal Screening’[Mesh], ‘Hearing Disorders’[Mesh], ‘Costs and Cost Analysis’[Mesh], ‘Decision Support
Techniques’[Mesh], ‘Germany’[Mesh]Background
In Germany, the prevalence of congenital hearing
impairments is approximately 1.2 cases per 1,000 new-
borns [1]. Newborn hearing screening is used ‘to identify
hearing impairments shortly after birth to initiate treat-
ment as soon as possible and to allow affected children* Correspondence: Astrid.Langer@lgl.bayern.de
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reproduction in any medium, provided the orto enjoy largely normal development’ (p. 130) [2]. A sys-
tematic review of newborn hearing screening by Wolff
et al. [2] found that screening, and earlier treatment,
were both associated with better language development.
These findings are supported by a recent review [3].
In Germany, newborn hearing screening for the early
detection of hearing impairment was legally mandated
in 2008 and came into effect on 1 January 2009 [4].
Since then, all newborns insured by Statutory Health In-
surance in Germany have been entitled to newborn
hearing screening. In Germany, the primary aim of new-
born hearing screening is to detect bilateral hearing
impairments of 35 dB or more (using transient evokedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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brainstem response (AABR) in the first stage and AABR
in the second stage) in the first three months of life, and
to initiate treatment in the first six months of life. How-
ever, a nationwide tracking system – that is, a nation-
wide system to ensure completeness of participation and
the follow-up of newborns with positive (conspicuous)
hearing (screening) test results until diagnosis of hearing
impairment – was not included [4].
Several research groups have recently endorsed the
need for a tracking system. For instance, Rohlfs et al.
argue that ‘the implementation of newborn hearing
screening only makes sense if there exists an efficient
tracking system’ (p. 1453) [5]. In its report ‘Newborn
hearing screening in the detection of hearing impair-
ment’, the Institute for Quality and Efficiency in Health
Care found that, for early diagnosis and treatment, the
full-scale implementation of newborn hearing screening
may not be sufficient. They argue that substantial benefit
from newborn hearing screening can only be expected if
screening is reinforced by organizational structures
which ensure there are neither delays nor disruptions
from the point of initial suspicion of hearing impairment
to its subsequent treatment [1]. In a recent review, Ptok
points out that ‘the most important single measure for
the practical realization of early detection of hearing
impairments in newborns and infants in Germany seems
to be the installation of a system of tracking centers cov-
ering the whole country’ (p. 430) [6]. Furthermore, a re-
cent study on universal newborn hearing screening two
years after its full-scale implementation in Bavaria
showed that, in 49% of newborns with hearing impair-
ment, early diagnosis was only possible through the use
of a tracking system [7]. Therefore, in the absence of a
tracking system for follow-up of newborns with positive
(conspicuous) hearing (screening) test results until diag-
nosis of hearing impairment, early suspicion of hearing
impairment may not actually result in early detection
and treatment.
The aim of this study, therefore, was to assess the
cost-effectiveness of tracking newborns with bilateral
hearing impairment in Bavaria based on data from Bavarian
newborn hearing screening facilities in a decision-analytic
model.
Methods
Decision-analytic model: scope and perspective
In Germany, a nationwide newborn hearing screening
programme was implemented in 2009, but a tracking
system covering the whole country was not considered.
In May 2003, a newborn hearing screening programme
including a tracking system was initiated in the Upper
Palatinate based on an interdisciplinary design [8]. In
the pilot project, referred to as ‘newborn auditoryscreening’, consecutive TEOAE and AABR screening
tests were conducted. The Screening Centre at the Pub-
lic Health Authority was involved in coordinating the
screening process. It was responsible for the complete-
ness of participation, the follow-up of newborns with a
positive screening test result, and quality assurance of
the pilot project. For this purpose, the screening centre
maintained registers of newborns who had not been
screened and newborns with a positive (conspicuous)
screening test result. The tracking system established at
the screening centre was used, on the one hand, to
achieve a high coverage rate, i.e. a high proportion of
newborns screened, and on the other hand a low loss to
follow-up rate for subsequent tests. The interventions of
the tracking system included recalls by letter and tele-
phone and, if required, involvement of the public health
office. Data from the pilot project and Bavarian newborn
hearing screening facilities were, therefore, used to as-
sess the cost-effectiveness of the inclusion of a tracking
system within a newborn hearing screening programme.
These data were obtained from the Bavarian Food and
Health Safety Authority and some of them are publicly
available. A model-based cost-effectiveness analysis was
conducted from the perspective of the German Statutory
Health Insurance, taking into account the costs of track-
ing. Owing to a lack of long-term data, the time horizon
of the model was limited to the newborn hearing screen-
ing programme (initial hearing screening test and subse-
quent hearing tests or diagnosis). Therefore, discounting
was not relevant. The model included the costs of the
initial hearing screening test and subsequent hearing
tests, costs of diagnosis, and costs of tracking. Only bi-
lateral hearing impairment of 35 dB or more was consid-
ered, as is standard practice in Germany. Moreover,
there is a lack of evidence concerning the benefits of
early detection in newborns with unilateral hearing im-
pairment in terms, for example, of language and speech
development [9]. Therefore, the outcome measure of the
economic analysis was the cost per case of bilateral hear-
ing impairment detected.
There are several good-practice guidelines for
decision-analytic modelling in health economic evalu-
ation [10-16]. The decision-analytic model developed
here follows the guidelines established by Philips et al.
[10], as these are the result of a review and synthesis of
existing good practice guidelines. With regard to the
model’s technical documentation, the guidelines on
modelling provided by the Institute on Quality and Effi-
ciency in Health Care were followed [16]. TreeAge Pro
2011 software was used to build a static decision tree
model, which is appropriate for the analysis of the prob-
abilities of events characterized by limited change or re-
currence over time, such as the probability that a
newborn is hearing impaired or not [17-19].
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The structure of the decision tree is largely based on the
test procedure of the pilot project ‘newborn auditory
screening’ [8]. The structure of the decision tree was
also informed by existing decision tree models concern-
ing newborn hearing screening [20,21] and is shown in
Figure 1. In Germany, a two-stage newborn hearing
screening programme performed in hospital before dis-
charge should immediately be followed by confirmatory
diagnostic evaluation [4]. As there are not enough
pediatric audiologists or otolaryngologists with expertise
in phoniatry and pedaudiology to perform confirmatory
diagnostic evaluation, in the pilot project ‘newborn audi-
tory screening’, up to two other hearing tests (AABR,
otoacoustic emissions (OAE), or both OAE and AABR)
were performed after discharge from hospital, and before
referral to pediatric audiologists or otolaryngologists
with expertise in phoniatry and pedaudiology for con-
firmatory diagnostic evaluation. Therefore, the decision
tree includes a four-stage test procedure for newborns
that bilaterally fail the first, second, and third hearing
tests – that is to say, newborns who have a positive bilat-
eral hearing impairment test result are scheduled for an
additional hearing test. Whereas the first hearing test is
a two-stage screening procedure (first TEOAE or AABRFigure 1 Structure of the model.and then, if the TEOAE or AABR screening test result is
positive, AABR), the other hearing tests are one-stage
tests using OAE, AABR, or both OAE and AABR. New-
borns do not run through the four-stage test procedure
in the following four cases: they are not screened; they
are lost to follow-up after the first, second, or third test;
they pass the first, second, or third test (i.e. have no
evidence of bilateral hearing impairment); or they uni-
laterally fail the first, second, or third test. Newborns
with bilateral hearing impairment in this group may be
identified at a later date outside the newborn hearing
screening programme, for example due to parental con-
cern. As these newborns are not identified at an early
stage as a consequence of screening, they are not
counted as part of the yield of the four-stage test pro-
cedure [20].
Decision-analytic model: variable estimation
Table 1 gives the probabilities of events related to the
four-stage test procedure. These probabilities were taken
from published and unpublished data in the pilot project
‘newborn auditory screening’ [8] and, where data from
the pilot project were not available, from Bavarian new-
born hearing screening facilities for 2010. The data
include the probability that the newborn is lost to




p_Ltfu1_t Probability of loss to follow-up before the initial hearing
screening test with tracking
0.045 (0.043; 0.047) Pilot project ‘newborn auditory
screening’ [8]
p_Ltfu1_nt Probability of loss to follow-up before the initial hearing
screening test without tracking
0.053 (0.051; 0.055) Pilot project ‘newborn auditory
screening’ [8]
p_Ltfu2_t Probability of loss to follow-up before 2nd test with tracking 0.07 (0.057; 0.084) Data from the state-wide screening
programme for 2010
p_Ltfu2_nt Probability of loss to follow-up before 2nd test without
tracking
0.51 (0.497; 0.524) Data from the state-wide screening
programme for 2010
p_Ltfu3_t Probability of loss to follow-up before 3rd test with tracking 0.08 (0.048; 0.117) Data from the state-wide screening
programme for 2010
p_Ltfu3_nt Probability of loss to follow-up before 3rd test without
tracking
0.29 (0.256; 0.325) Data from the state-wide screening
programme for 2010
p_Ltfu4_t Probability of loss to follow-up before 4th test with
tracking
0.07 (0.027; 0.133) Data from the state-wide screening
programme for 2010
p_Ltfu4_nt Probability of loss to follow-up before 4th test without
tracking
0.18 (0.133; 0.239) Data from the state-wide screening
programme for 2010
p_fail_1st_test Probability of failing the initial hearing screening test
bilaterally
0.006 (0.005; 0.007) Pilot project ‘newborn auditory
screening’ [8]
p_fail_2nd_test Probability of failing the 2nd test bilaterally 0.202 (0.167; 0.241) Pilot project ‘newborn auditory
screening’*
p_fail_3rd_test Probability of failing the 3rd test bilaterally 0.627 (0.512; 0.739) Pilot project ‘newborn auditory
screening’*
p_fail_4th_test Probability of failing the 4th test bilaterally 0.609 (0.400; 0.785) Pilot project ‘newborn auditory
screening’*
p_diagnosis_after_2nd_test Probability of diagnosis after 2nd test 0.11 (0.073; 0.159) Data from the state-wide screening
programme for 2010
p_diagnosis_after_3rd_test Probability of diagnosis after 3rd test 0.36 (0.261; 0.460) Data from the state-wide screening
programme for 2010
*unpublished data.
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the newborn is not screened) or to subsequent tests,
with and without tracking; that it bilaterally fails the first
or subsequent tests; and that it is diagnosed after the
second or third test. The probability of failing the first
test was estimated from the number of newborns who
fail the first test divided by the number of newbornsTable 2 Cost items used to calculate the costs of hearing (scr
Name Description
c_OAE_inpatient Costs of OAE performed in hospital
c_AABR_inpatient Costs of AABR performed in hospital
c_lumpsum_ENT Lump sum for office-based ENT physicians
c_OAE_outpatient_ENT Costs of OAE performed by office-based ENT
c_AABR_outpatient_ENT Costs of AABR performed by office-based ENT
c_lumpsum_PA Lump sum for office-based pediatric audiolog
c_AABR_outpatient_PA Costs of AABR performed by office-based ped
c_MEM_reflex_outpatient_PA Costs of impedance test of the middle ear pe
office-based pediatric audiologists
AABR: automated auditory brainstem response; CI: confidence interval; DKG-NT: ‘De
Bewertungsmaßstab’; ENT: ear, nose, and throat; MEM: middle ear muscle; OAE: otoscreened. The probability of failing subsequent tests was
conditional on having failed previous tests.
Table 2 shows the cost items used to calculate the
costs of hearing (screening) tests and diagnosis, and
Table 3 provides the costs of the initial hearing screening
test, subsequent tests, and diagnosis. It is assumed that
the first test – that is, the initial hearing screening test –eening) tests and diagnosis
Item Points Point value Mean Source
1409 400 8.589704 Cent €34.36 DKG-NT [22]
1408 888 8.589704 Cent €76.28 DKG-NT [22]
09210 680 3.5048 Cent €23.83 EBM [23]
physicians 09324 340 3.5048 Cent €11.92 EBM [23]
physicians 01706 705 3.5048 Cent €24.71 EBM [23]
ists 20210 865 3.5048 Cent €30.32 EBM [23]
iatric audiologists 20327 1535 3.5048 Cent €53.80 EBM [23]
rformed by 20323 220 3.5048 Cent €7.71 EBM [23]
utsche Krankenhausgesellschaft-Normaltarif’; EBM: ‘Einheitlicher
acoustic emissions; PA: pediatric audiologist.
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tests are performed by office-based ear, nose, and throat
(ENT) physicians. Newborns who fail the second, third,
or fourth test by pediatric audiologists receive a final
diagnosis. Office-based ENT physicians and office-based
pediatric audiologists receive a specific lump sum in
addition to the costs of the tests. In order to confirm or
exclude bilateral hearing impairment, pediatric audiolo-
gists perform AABR and an impedance test of the mid-
dle ear. As inpatient services in Germany are generally
reimbursed as a lump sum by diagnosis-related groups
(DRGs), costs for inpatient tests (i.e. the first test) were
estimated based on the tariff scheme of the German
Hospital Federation (DKG-NT [22]). Costs for out-
patient tests (i.e. the second, third, and fourth tests),
were taken from the doctor’s fee scale (EBM [23]). All
costs were calculated as the product of points and point
value (point price). The costs for tests were weighted by
the probability that a newborn receives OAE, AABR, or
both OAE and AABR. These probabilities were taken
from the pilot project and based on assumptions. Unlike
the other tests, the first test is a two-stage screening test:
in the first stage, 95.2% of newborns are screened by
OAE and 4.8% by AABR; in the second stage, all
newborns who bilaterally fail the initial screening
test (7.66%) are screened by AABR. The probability
of using both OAE and AABR was 10.4% for the
second test, 20.9% for the third test, and 0% for
diagnostic tests performed by pediatric audiologists.
The probability of using OAE or AABR was respect-
ively 74.7% or 14.9% for the second test, 40.3% or
38.8% for the third, and 0% or 100% for tests per-
formed by pediatric audiologists. The costs of tests
were €42.22 for the first test, €38.99 for the second
test, €43.39 for the third test, and €91.83 for diag-
nostic tests performed by pediatric audiologists. The
costs of tracking were taken from the pilot project







c_1st_test_2stagesa 95.2e/0f 4.8e/7.66f 0e/0f
c_2nd_test_1stage_ENTb 74.7 14.9 10.4
c_3rd_test_1stage_ENTc 40.3 38.8 20.9
c_test_PAd 0 100 0
aCosts of the initial two-stage hearing screening test performed in hospital; bCosts o
performed by office-based ENT physicians; dCosts of confirmatory diagnostic testing
included in costs of AABR; AABR: automated auditory brainstem response, ENT: ear,
pediatric audiologist.€4.55 per newborn screened (total costs of tracking divided
by the number of newborns screened). A detailed break-
down of the costs of tracking is provided in Table 4.Decision-analytic model: uncertainty and consistency
The decision-analytic model was developed and vali-
dated by discussion with experts in the provision of
newborn hearing screening. In order to reflect uncer-
tainty, both deterministic and probabilistic sensitivity
analyses were performed to show how the model’s out-
puts change with variation in its inputs. In univariate
sensitivity analyses, parameters were varied by ±50%. A
beta distribution was assumed for all probabilities and a
gamma distribution for all cost parameters [17]. A struc-
tural sensitivity analysis was also performed to analyse
how the results change with a variation in the test pro-
cedure – that is, all children are supposed to be diag-
nosed after the second or third test.Data analysis
Economic evaluation examines both the costs and the
effects of two or more alternatives and thus provides infor-
mation that can be used to optimize (usually: maximize) ef-
fectiveness in relation to the resources available [18].
Differences in costs (C) and effects (E) are related using in-
cremental cost-effectiveness ratios (ICERs). Here, the ICER
is defined as: (Ctracking–Cno tracking)/(Etracking–Eno tracking).
The ICER was used as the primary outcome measure in the
economic analysis to compare tracking with no tracking.
The results of the base case analysis and the sensitivity ana-
lyses are presented in the tables, a scatter plot, and a cost-
effectiveness acceptability curve. As there is no evidence as
to what is the maximum a decision-maker is willing to pay
for an additional detected case of bilateral hearing impair-
ment, a range of thresholds for cost-effectiveness was used,










f 2nd test performed by office-based ENT physicians; cCosts of 3rd test
performed by pediatric audiologists; e1st stage; f2nd stage; gCosts of OAE are
nose, and throat, MEM: middle ear muscle, OAE: otoacoustic emissions, PA:
Table 4 Costs of tracking from the pilot project ‘newborn
auditory screening
Personnel expenses
Nurse (0.75 position; tariff part: E8) €33,876
Epidemiologist (0.5 position; tariff part: E14) €31,759
Personnel expenses total €65,635
Non-personnel expenses
Printing costs (flyer, data sheets) €1,500
Stamped addressed envelopes for hospitals
and doctors’ offices (50 per week)
€1,590
Telephone/fax (40 per working day) €1,000
Room €4,200
Two desktop PCs €3,000
One telephone (nationwide connection) €100
Letters (eight per working day) €1,000
Non-personnel expenses total €12,390
Total costs €78,025
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Decision-analytic model: base case analysis
The estimated effects and costs were combined in an
ICER to calculate the incremental cost of detecting one
additional case of bilateral hearing impairment. The base
case analysis of the model is shown in Table 5. In the
base case, the cost per case of bilateral hearing impair-
ment detected was €40.12 for no tracking and €40.63 for
tracking. In a hypothetical cohort of 100,000 newborns,
the number of cases of bilateral hearing impairment
detected with no tracking was 21, and with tracking 51.
The ICER of tracking vs. no tracking was €1,697 per
additional case of bilateral hearing impairment detected.
Compared with no tracking, tracking resulted in more
cases of bilateral hearing impairment detected as well as
higher costs.
Decision-analytic model: sensitivity analyses
Table 6 shows the results of the univariate sensitivity
analyses. It was found that the higher the probability of
loss to follow-up before the second and consecutive tests
with tracking, the higher the ICER; the lower the prob-
ability of loss to follow-up before the second and con-
secutive tests with no tracking, the higher the ICER; and
the higher the costs of tracking, the higher the ICER.
Overall, the results were relatively robust in the univari-
ate sensitivity analyses: the ICER varied between €1,419
(probability of loss to follow-up before second testTable 5 Base case analysis of the model
Intervention Costs Effects (cases detected) ACER: Cost per ca
Tracking €40.63 0.00051 €79,667
No tracking €40.12 0.00021 €191,048
ACER: average cost-effectiveness ratio; ICER: incremental cost-effectiveness ratio.without tracking = 0.77) and €2,297 (probability of loss
to follow-up before second test without tracking = 0.26)
per additional case of bilateral hearing impairment
detected.
Figure 2 shows that the ICER in the second-order
Monte Carlo simulation ranged from €1,060 to €2,769.
In Figure 3, the cost-effectiveness acceptability curve
shows that, at a willingness to pay of €2,000 or €2,500
per additional case of bilateral hearing impairment
detected, the probability that tracking is cost-effective
was 83.8% or 99.5%, respectively.
The structural sensitivity analysis revealed that if all
children were referred to pediatric audiologists and
received a final diagnosis after the second or third test,
the ICER would be €954 or €1,309 per case of bilateral
hearing impairment detected.
Discussion
Using a decision-analytic model based on data from Bav-
arian newborn hearing screening facilities, the cost-
effectiveness of tracking newborns with bilateral hearing
impairment in Bavaria was assessed. The costs of track-
ing in Bavaria – that is, €4.55 – compare well with those
from a cost analysis of universal newborn hearing
screening in Hesse, in which the costs of tracking were
estimated at €4.00 [24]. According to a recent literature
review [25], this is the first model to assess the cost-
effectiveness of tracking within a newborn hearing
screening programme; therefore the results of this model
are not directly comparable with those of other models.
However, with an ICER of €1,697 per additional detected
case of bilateral hearing impairment, the implementation
of a tracking system within a newborn hearing screening
programme may be cost-effective, in particular with re-
gard to the lifelong benefits of early detection and treat-
ment, such as increased productivity owing to better
language outcomes. In the pilot project, it is reported
that from 2003 to 2008 there were 51 cases of confirmed
bilateral hearing loss detected out of 73,332 infants
screened, resulting in a rate of 0.70 per 1,000. That is
higher than the rate of 0.51 per 1,000 with tracking used
in the model. In the pilot project, 48% of the children
with bilateral hearing impairment were followed up
solely because of the existence of the tracking centre.
Therefore, 27 cases of bilateral hearing impairment
would have been diagnosed in the absence of the track-
ing programme, resulting in a rate of 0.5 per 1,000, com-
pared with 0.31 per 1,000 in the decision-analytic model.se detected ICER: Incremental cost per additional case detected
-
€1,697
Table 6 Univariate sensitivity analyses














0.04 40.12 40.64 0.52 0.00021 0.00053 0.00032 1,628
0.07* 40.12* 40.63* 0.51* 0.00021* 0.00051* 0.00030* 1,697*
0.11 40.12 40.62 0.50 0.00021 0.00050 0.00029 1,775














0.26 40.19 40.63 0.44 0.00032 0.00051 0.00019 2,297
0.51* 40.12* 40.63* 0.51* 0.00021* 0.00051* 0.00030* 1,697*
0.77 40.04 40.63 0.59 0.00010 0.00051 0.00041 1,419














0.04 40.12 40.64 0.52 0.00021 0.00053 0.00032 1,620
0.08* 40.12* 40.63* 0.51* 0.00021* 0.00051* 0.00030* 1,697*
0.12 40.12 40.63 0.51 0.00021 0.00050 0.00029 1,793














0.15 40.12 40.63 0.51 0.00024 0.00051 0.00027 1,853
0.29* 40.12* 40.63* 0.51* 0.00021* 0.00051* 0.00030* 1,697*
0.44 40.11 40.63 0.52 0.00018 0.00051 0.00033 1,551














0.04 40.12 40.63 0.51 0.00021 0.00052 0.00031 1,663
0.07* 40.12* 40.63* 0.51* 0.00021* 0.00051* 0.00030* 1,697*
0.11 40.12 40.63 0.51 0.00021 0.00050 0.00029 1,740














0.09 40.12 40.63 0.51 0.00022 0.00051 0.00029 1,737
0.18* 40.12* 40.63* 0.51* 0.00021* 0.00051* 0.00030* 1,697*
0.27 40.12 40.63 0.51 0.00020 0.00051 0.00031 1,657














2.28 40.12 40.62 0.50 0.00021 0.00051 0.00030 1,654
4.55* 40.12* 40.63* 0.51* 0.00021* 0.00051* 0.00030* 1,697*
6.83 40.12 40.65 0.53 0.00021 0.00051 0.00030 1,740
aProbability of loss to follow-up before 2nd test with tracking; bProbability of loss to follow-up before 2nd test without tracking; cProbability of loss to follow-up
before 3rd test with tracking; dProbability of loss to follow-up before 3rd test without tracking; eProbability of loss to follow-up before 4th test with tracking;
fProbability of loss to follow-up before 4th test without tracking; gCosts of tracking *Value in base case analysis; ICER: incremental cost-effectiveness ratio.
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as a result of tracking is the same: 0.20 per 1,000.
Several economic evaluations have shown that the
short-term cost-effectiveness of a newborn hearing
screening programme depends not only on the diagnos-
tic accuracy of the screening test procedure, but also on
the ability to ensure follow-up of newborns with positive
screening test results [20,26]. Tracking systems are,
therefore, needed to ensure that early detection results
in early intervention without unnecessary delays. Further
studies are needed to evaluate the cost-effectiveness of
tracking systems within newborn screening programmes.The model used here has several limitations. First, it is
assumed that, at the end of the four-stage test proced-
ure, bilateral hearing impairment can be definitively con-
firmed or excluded. However, in contrast to other
decision-analytic models which assume conditional inde-
pendence, it could be considered that the probability
that a newborn fails subsequent tests is conditional on
having previous positive test results. However, this
required the merging of data from two different new-
born hearing screening programmes with different refer-
ral rates and rates of diagnosis conditional on referral.
This merging of data could result in an underestimation
Figure 2 Incremental cost-effectiveness scatter plot for the model.
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ence of both newborn hearing screening programmes.
Second, some of the data used are taken from a Bavar-
ian pilot project, and these data may therefore differ
from data compiled subsequent to the nationwide imple-
mentation of newborn hearing screening in 2009, as well
as data from other newborn hearing screeningFigure 3 Cost-effectiveness acceptability curve for the model.programmes in Germany. This may have implications
for the generalizability of results; however, the issue of
generalizability was addressed in the sensitivity analyses.
Third, only parameter and structural uncertainty was
addressed via the sensitivity analyses, whereas methodo-
logical uncertainty (for example, discount rate, long time
horizon) was not addressed, owing to a lack of long-
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different patient groups (uni- and/or bilateral hearing
impairment) was not assessed because the target popula-
tion was newborns with bilateral hearing impairment
only, as is standard practice in Germany [4]. Thus, the
analysis is rather conservative. If centralized tracking
was extended to include unilateral referrals – some of
which may indeed result in the diagnosis of bilateral
hearing impairment – the incremental cost-effectiveness
ratio would presumably be lower. A recent study found
that children with unilateral hearing loss had worse lan-
guage skills than their siblings with normal hearing [27].
However, more research is needed to clarify this issue.
Fourth, owing to a lack of adequate data, the time
horizon was limited to the newborn hearing screening
programme (initial hearing screening test and subse-
quent hearing tests or diagnosis) and a scenario analysis
was not conducted.
Several studies have shown that the economic and dis-
ease burden of hearing impairment is high. The societal
cost of severe to profound hearing loss over the lifetime
of an affected person in the United States was estimated
at US$297,000, mainly resulting from productivity losses
(63%) and the requirement for special education (21%)
[28]. Furthermore, permanent bilateral hearing impair-
ment in children between 7 and 9 years of age was found
to be associated with reduced health status and health-
related quality of life compared with children with nor-
mal hearing [29], and an expected cost to society of
about £14,000 in the preceding year of life [30]. There-
fore, if a longer time horizon was taken into account, a
transsectoral or even societal perspective on the effects
on health-related quality of life would favour a newborn
hearing screening programme which included tracking.
Tracking may even be cost-saving from the perspective
of public health services themselves (who pay for the
tracking) once public expenditures for schooling etc. for
children with special needs are taken into account. How-
ever, adequate and robust data on the long-term effects
of tracking within newborn screening programmes with
respect to costs and outcomes are lacking.
Conclusions
Switching from no tracking to tracking costs €1,697 for
each additional case of bilateral hearing impairment
detected. If society is willing to pay at least €1,697 per
additional case of bilateral hearing impairment detected,
tracking can be recommended. Tracking may be even
cost-saving in the long term if a high proportion of bilat-
erally hearing-impaired children go on to achieve normal
language skills and so enjoy increased lifetime productiv-
ity, as a result of the early intervention thereby enabled.
The cost-effectiveness of a newborn hearing screening
programme does not depend only on the accuracy of theprogramme, but also on the ability to ensure follow-up
of newborns that do not pass the initial hearing screen-
ing test and subsequent tests. Overall, then, this eco-
nomic analysis is rather conservative because an
outcome measure for the earliness of diagnosis was not
included.
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